CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

No sooner did Moderna (MRNA) and Merck & Co. (MRK) announce additional positive data for their cancer vaccine candidate, a messenger RNA (mRNA)-based individualized neoantigen therapy (INT), than ...

CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in ...

CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 ...

FDA was considering reviewing them simultaneously for a side-by-side comparison. The Food and Drug Administration will hold meetings to review vaccines for children under 5 in June, it announced ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.

Leading vaccine makers Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) on Wednesday responded to President Donald Trump’s recent criticism that drug companies have yet to justify the success of their ...

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, ...